Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis: myelodysplastic syndrome
Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the Phase 1 EXPLORER (NCT0256198) and Phase 2 PATHFINDER (NCT03580655) trials (N =...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
05 July 2022
|
| In: |
Leukemia
Year: 2022, Jahrgang: 36, Heft: 8, Pages: 2108-2120 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/s41375-022-01615-z |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41375-022-01615-z Verlag, kostenfrei, Volltext: http://www.nature.com/articles/s41375-022-01615-z 
|
| Verfasserangaben: | Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H. Radia, Johannes Lübke, Priyanka J. Bobbili, Aolin Wang, Chelsea Norregaard, Saša Dimitrijevic, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene A. Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Andi Chin, Selvam R. Sendhil, Mei Sheng Duh, Peter Valent and Daniel J. DeAngelo |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1868839656 | ||
| 003 | DE-627 | ||
| 005 | 20250115015927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231031s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41375-022-01615-z |2 doi | |
| 035 | |a (DE-627)1868839656 | ||
| 035 | |a (DE-599)KXP1868839656 | ||
| 035 | |a (OCoLC)1425216584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Reiter, Andreas |d 1964- |e VerfasserIn |0 (DE-588)172629551 |0 (DE-627)697563766 |0 (DE-576)133488594 |4 aut | |
| 245 | 1 | 0 | |a Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis |b myelodysplastic syndrome |c Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H. Radia, Johannes Lübke, Priyanka J. Bobbili, Aolin Wang, Chelsea Norregaard, Saša Dimitrijevic, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene A. Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Andi Chin, Selvam R. Sendhil, Mei Sheng Duh, Peter Valent and Daniel J. DeAngelo |
| 264 | 1 | |c 05 July 2022 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.10.2023 | ||
| 520 | |a Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the Phase 1 EXPLORER (NCT0256198) and Phase 2 PATHFINDER (NCT03580655) trials (N = 176) and patients treated with best available therapy (BAT; N = 141). A multi-center, observational, retrospective chart review study was conducted at six study sites (four European, two American) to collect data from patients with AdvSM who received BAT; these data were pooled with data from EXPLORER and PATHFINDER. Comparisons between outcomes of OS, duration of treatment (DOT), and maximum reduction in serum tryptase were conducted between the treatment cohorts, with adjustment for key covariates. The results indicated that the avapritinib cohort had significantly better survival (adjusted hazard ratio (HR) (95% confidence interval (CI)): 0.48 (0.29, 0.79); p = 0.004) and significantly longer DOT (HR: 0.36 (0.26, 0.51); p < 0.001) compared to the BAT cohort. Additionally, the mean difference in percentage maximum reduction in serum tryptase levels was 60.3% greater in the avapritinib cohort (95% CI: −72.8, −47.9; p < 0.001). With no randomized controlled trials comparing avapritinib to BAT, these data offer crucial insights into the improved efficacy of avapritinib for the treatment of AdvSM. | ||
| 650 | 4 | |a Cancer therapy | |
| 650 | 4 | |a Targeted therapies | |
| 700 | 1 | |a Gotlib, Jason |e VerfasserIn |4 aut | |
| 700 | 1 | |a Álvarez-Twose, Iván |e VerfasserIn |4 aut | |
| 700 | 1 | |a Radia, Deepti H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lübke, Johannes |d 1996- |e VerfasserIn |0 (DE-588)1189769867 |0 (DE-627)1668483645 |4 aut | |
| 700 | 1 | |a Bobbili, Priyanka J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Aolin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Norregaard, Chelsea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dimitrijevic, Saša |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sullivan, Erin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Louie-Gao, Melinda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schwaab, Juliana |d 1982- |e VerfasserIn |0 (DE-588)1051912687 |0 (DE-627)787019399 |0 (DE-576)407558764 |4 aut | |
| 700 | 1 | |a Galinsky, Ilene A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perkins, Cecelia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sperr, Wolfgang R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sriskandarajah, Priya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chin, Andi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sendhil, Selvam R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Duh, Mei Sheng |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Valent, Peter |d 1962- |e VerfasserIn |0 (DE-588)1112048979 |0 (DE-627)866035079 |0 (DE-576)47634705X |4 aut | |
| 700 | 1 | |8 2\p |a DeAngelo, Daniel J. |e VerfasserIn |0 (DE-588)1018240942 |0 (DE-627)68774413X |0 (DE-576)359502342 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 36(2022), 8, Seite 2108-2120 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis myelodysplastic syndrome |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:8 |g pages:2108-2120 |g extent:13 |a Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis myelodysplastic syndrome |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41375-022-01615-z |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://www.nature.com/articles/s41375-022-01615-z |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20231031 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1051912687 |a Schwaab, Juliana |m 1051912687:Schwaab, Juliana |d 60000 |d 61200 |e 60000PS1051912687 |e 61200PS1051912687 |k 0/60000/ |k 1/60000/61200/ |p 12 | ||
| 998 | |g 1189769867 |a Lübke, Johannes |m 1189769867:Lübke, Johannes |d 60000 |d 61200 |e 60000PL1189769867 |e 61200PL1189769867 |k 0/60000/ |k 1/60000/61200/ |p 5 | ||
| 998 | |g 172629551 |a Reiter, Andreas |m 172629551:Reiter, Andreas |d 60000 |d 61200 |e 60000PR172629551 |e 61200PR172629551 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1868839656 |e 4400302644 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1868839656","note":["Gesehen am 31.10.2023"],"name":{"displayForm":["Andreas Reiter, Jason Gotlib, Iván Álvarez-Twose, Deepti H. Radia, Johannes Lübke, Priyanka J. Bobbili, Aolin Wang, Chelsea Norregaard, Saša Dimitrijevic, Erin Sullivan, Melinda Louie-Gao, Juliana Schwaab, Ilene A. Galinsky, Cecelia Perkins, Wolfgang R. Sperr, Priya Sriskandarajah, Andi Chin, Selvam R. Sendhil, Mei Sheng Duh, Peter Valent and Daniel J. DeAngelo"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia"}],"part":{"text":"36(2022), 8, Seite 2108-2120","pages":"2108-2120","volume":"36","issue":"8","extent":"13","year":"2022"},"id":{"eki":["32046699X"],"issn":["1476-5551"],"zdb":["2008023-2"]},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedDisp":"1997-"}],"note":["Gesehen am 15.03.04"],"pubHistory":["Nachgewiesen 11.1997 -"],"recId":"32046699X","disp":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis myelodysplastic syndromeLeukemia"}],"physDesc":[{"extent":"13 S."}],"person":[{"role":"aut","given":"Andreas","display":"Reiter, Andreas","family":"Reiter"},{"role":"aut","display":"Gotlib, Jason","family":"Gotlib","given":"Jason"},{"role":"aut","given":"Iván","display":"Álvarez-Twose, Iván","family":"Álvarez-Twose"},{"given":"Deepti H.","family":"Radia","display":"Radia, Deepti H.","role":"aut"},{"role":"aut","given":"Johannes","family":"Lübke","display":"Lübke, Johannes"},{"role":"aut","given":"Priyanka J.","display":"Bobbili, Priyanka J.","family":"Bobbili"},{"role":"aut","display":"Wang, Aolin","family":"Wang","given":"Aolin"},{"role":"aut","family":"Norregaard","display":"Norregaard, Chelsea","given":"Chelsea"},{"role":"aut","family":"Dimitrijevic","display":"Dimitrijevic, Saša","given":"Saša"},{"given":"Erin","display":"Sullivan, Erin","family":"Sullivan","role":"aut"},{"family":"Louie-Gao","display":"Louie-Gao, Melinda","given":"Melinda","role":"aut"},{"given":"Juliana","family":"Schwaab","display":"Schwaab, Juliana","role":"aut"},{"given":"Ilene A.","family":"Galinsky","display":"Galinsky, Ilene A.","role":"aut"},{"display":"Perkins, Cecelia","family":"Perkins","given":"Cecelia","role":"aut"},{"role":"aut","display":"Sperr, Wolfgang R.","family":"Sperr","given":"Wolfgang R."},{"role":"aut","given":"Priya","display":"Sriskandarajah, Priya","family":"Sriskandarajah"},{"role":"aut","family":"Chin","display":"Chin, Andi","given":"Andi"},{"role":"aut","given":"Selvam R.","family":"Sendhil","display":"Sendhil, Selvam R."},{"role":"aut","given":"Mei Sheng","family":"Duh","display":"Duh, Mei Sheng"},{"role":"aut","display":"Valent, Peter","family":"Valent","given":"Peter"},{"role":"aut","given":"Daniel J.","family":"DeAngelo","display":"DeAngelo, Daniel J."}],"title":[{"title_sort":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","subtitle":"myelodysplastic syndrome"}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"05 July 2022"}],"id":{"doi":["10.1038/s41375-022-01615-z"],"eki":["1868839656"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a REITERANDREFFICACYOF0520 | ||